论文部分内容阅读
目的观察缬沙坦治疗病态窦房结综合征(sick sinus syndrome,SSS)患者植入起搏器后阵发性心房颤动的效果。方法选择2014年1月—2015年2月本院收治的SSS患者62例作为研究对象,均植入双腔起搏器,合并阵发性心房颤动。随机分为对照组与干预组各31例。对照组不进行药物干预,观察组给予缬沙坦口服治疗。比较干预3、6、9、12个月两组左房舒张末内径,计算每3个月的累积房颤发作频率及房颤发作总时间。计量资料采用t检验,P<0.05为差异有统计学意义。结果干预6、9、12个月,干预组房颤频率分别为(36.1±2.4)、(33.2±3.0)、(31.0±2.8)次/3个月,均低于对照组的(38.6±3.5)、(37.9±3.5)、(37.1±2.9)次/3个月,差异均有统计学意义(均P<0.05)。干预6、9、12个月,干预组房颤持续总时间分别为(420.6±45.3)、(410.5±37.6)、(385.6±46.0)min/3个月,均短于对照组的(450.6±51.7)、(467.2±40.2)、(479.5±54.3),差异均有统计学意义(均P<0.05)。结论缬沙坦可降低SSS患者植入起搏器后阵发性心房颤动的发作频率及持续总时间,值得进一步临床推广应用。
Objective To observe the effect of valsartan in the treatment of patients with sick sinus syndrome (SSS) after implantation of pacemaker after paroxysmal atrial fibrillation. Methods Sixty-two SSS patients admitted to our hospital from January 2014 to February 2015 were enrolled in this study. All patients underwent double-chamber pacemaker implantation with paroxysmal atrial fibrillation. Randomly divided into control group and intervention group of 31 cases. The control group without drug intervention, the observation group was given valsartan oral treatment. The left atrium diastolic diameter at 3, 6, 9, and 12 months was intervened to calculate the cumulative frequency of atrial fibrillation and the total time of atrial fibrillation episodes every 3 months. Measurement data using t test, P <0.05 for the difference was statistically significant. Results The frequency of atrial fibrillation in the intervention group was (36.1 ± 2.4), (33.2 ± 3.0) and (31.0 ± 2.8) times / 3 months, respectively, which were lower than those in the control group (38.6 ± 3.5 ), (37.9 ± 3.5) and (37.1 ± 2.9) times / 3 months respectively. The differences were statistically significant (all P <0.05). The total duration of atrial fibrillation in intervention group was (420.6 ± 45.3), (410.5 ± 37.6), (385.6 ± 46.0) min / 3 months after intervention at 6, 9 and 12 months, respectively, 51.7), (467.2 ± 40.2) and (479.5 ± 54.3), respectively, with significant differences (all P <0.05). Conclusion Valsartan can reduce the frequency and duration of paroxysmal atrial fibrillation after implantation of pacemaker in patients with SSS, which deserves further clinical application.